Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).


Code Company Price % Volume
NTL New Talisman Gold 0.002 100 1000000
ANL Amani Gold Ltd 0.0015 50 3911521
GGX Gas2Grid Limited 0.004 33 1554000
OAK Oakridge 0.002 33 1045677
BAS Bass Oil Ltd 0.0025 25 2799000
AJL AJ Lucas Group 0.039 22 187780
LEL Lithenergy 0.725 22 623131
RRR Revolverresources 0.375 21 294791
RBX Resource B 0.24 17 1157048
POL Polymetals Resources 0.145 16 13793

Resource Base (ASX:RBX) announced it was acquiring applications prospective for rare earths across the Murray Basin.

Lithium Energy (ASX:LEL) rose after telling shareholders its Burke Graphite Deposit is one of the highest-grade graphite deposits globally and that after test work it would re-engage with Chinese and Japanese parties who have previously expressed a strong interest in the graphite from the Burke Project.

And Bass Oil (ASX:BAS) rose after an update to shareholders on its ambitions to pursue Carbon Capture, Use and Storage (CCUS) at its Cooper Basin portfolio.


Code Company Price % Volume
ACB A-Cap Energy Ltd 0.085 -26 961103
BDC Bardoc Gold Ltd 0.045 -21 9544811
VMY Vimy Resources Ltd 0.18 -10 1073963
MCT Metalicity Limited 0.01 -9 761010
TOE Toro Energy Limited 0.03 -9 8590552
ERA Energy Resources 0.36 -9 522932
OKR Okapi Resources 0.525 -8 54361
PAR Paradigm Bio. 1.94 -8 242204
PEN Peninsula Energy Ltd 0.235 -8 2518717
GMR Golden Rim Resources 0.006 -8 7226

Bardoc Gold (ASX:BDC) fell after deferring the Final Investment Decision on its Bardoc Gold project and announcing a strategic review.

Paradigm Biopharmaceuticals (ASX:PAR) fell after receiving feedback from the FDA about its Investigational New Drug submission, resulting in the company having to modify its adrenal screening and mitigation plan.